Skip to main content
Premium Trial:

Request an Annual Quote

SCT, AB Biosciences Collaborate on Antibodies Using NGS

NEW YORK (GenomeWeb News) – Single Cell Technology and AB Biosciences today announced a collaboration aimed at identifying therapeutic antibodies.

SCT will use its technology called Antibody Biologix to massively screen plasma cells and measure the kinetics of secreted antibodies. It also will use next-generation sequencing to sequence the cognate light and heavy chain mRNA.

ABB will select antibody targets, engineer protein antigens, and develop tools for characterizing antibodies identified by SCT.

Financial and other terms of the collaboration were not disclosed.

Based in San Jose, Calif., SCT identifies and optimizes antibodies. On its website, it said that its platform analyzes antibodies and mRNA from individual antibody secreting cells. Antibodies are evaluated for their affinity and specificity, while mRNA encoding the cognate light and heavy chains is analyzed by NGS.

Allston, Mass.-based AB Biosciences engineers and produces niche protein molecules.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.